Is Madrigal Pharmaceuticals Inc (MDGL) a risky stock?
As of July 24, 2026, Clavix grades Madrigal Pharmaceuticals Inc (MDGL) B+ for risk, a composite score of 77 out of 100 on an A+ to F scale, which puts MDGL in the "solid" band. The grade is a risk read for educational purposes, not a buy or sell recommendation.
Grade as of July 24, 2026. Clavix regrades every trading day.
The five risk dimensions behind MDGL's grade
Each Clavix grade is a composite of five independent reads. Higher is safer. Here is how MDGL scores on each, as of July 24, 2026.
What's moving MDGL's risk right now
Company-specific signals Clavix flags behind MDGL's current grade, drawn from recent news and filings as of July 24, 2026.
New patents strengthen IP protection for Rezdiffra, MDGL's liver drug, and retail traders are talking about a possible acquisition. Analysts see 22-26% upside, but the company is still unprofitable with a -$13.50 EPS and -49% ROE.
Madrigal and Ribo reached their first major milestone in developing siRNA therapies for MASH, moving beyond the existing Rezdiffra franchise. The progress validates the partnership and could expand Madrigal's MASH pipeline.
Recent MDGL news
The latest headlines Clavix ingested for Madrigal Pharmaceuticals Inc, newest first. These feed the news-sentiment dimension of MDGL's grade.
-
Madrigal Pharmaceuticals (MDGL), a $12.76 billion biotech focused on MASH therapeutics, is highlighted with 22.65% potential upside. The stock trades at $553.48 within a 52-week range of $289.88-$602.83, with a forward P/E of 44.71 reflecting growth expectations, while posting 126.80% revenue growth alongside negative EPS of -13.50 and ROE of -49.35%.
What a B+ grade means
On the Clavix A+ to F scale, MDGL's composite of 77 falls in the B band (65–79), read as "solid." The scale is fixed, so the meaning never moves.
This page is generated from Clavix's own risk model and is for educational purposes only. It is not investment advice or a recommendation to buy or sell MDGL or any security. Grades are risk indicators, not predictions of return. Data may be delayed.